Christin Zuendorf, Chief Business Officer at TQ Therapeutics, brings strong expertise in commercial strategy of advanced cell therapies, with a particular focus on CAR-T technology and innovative manufacturing solutions. Her leadership helps bridge innovation and real-world implementation — ensuring that groundbreaking CAR-T therapies reach patients in need, when they need them.At TQ Therapeutics, innovation meets precision.As part of Work Package 6 - Point-of-care device manufacturing, TQ Therapeutics contributes its proprietary affinity- and column-based T-cell isolation technology, enabling rapid and efficient cell selection directly from patient’s whole blood.Together with collaborators including TQ Therapeutics, the EASYGEN Consortium is tackling one of the most significant challenges in cell therapy: the scalable manufacturing of CAR-T cell therapies at the point of care.Collaboration. Innovation. Access.That’s what EASYGEN — and its partners like TQx — stand for.#CART #PatientAccess #PointOfCare #LifeSciences